GTx, Inc.
(NASDAQ : GTXI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.20%83.100.9%$974.49m
KITEKite Pharma, Inc.
0.03%179.3616.1%$742.33m
CELGCelgene Corporation
0.41%144.481.1%$499.77m
AMGNAmgen Inc.
0.09%185.921.1%$483.58m
BIIBBiogen Inc.
-0.07%318.251.2%$422.08m
REGNRegeneron Pharmaceuticals, Inc.
1.48%439.142.7%$359.60m
ALNYAlnylam Pharmaceuticals, Inc
1.63%115.6510.7%$249.72m
ALXNAlexion Pharmaceuticals, Inc.
0.50%143.531.9%$230.11m
JUNOJuno Therapeutics, Inc.
-4.79%42.9814.6%$225.42m
VRTXVertex Pharmaceuticals Incorporated
-1.38%149.171.9%$208.45m
INCYIncyte Corporation
-1.15%109.582.6%$205.27m
ILMNIllumina, Inc.
-0.68%200.053.5%$158.33m
BLUEBluebird Bio, Inc.
1.17%130.2519.3%$143.09m
BMRNBioMarin Pharmaceutical Inc.
-0.85%94.144.4%$136.21m
CLVSClovis Oncology, Inc.
-2.78%76.3818.0%$132.65m

Company Profile

GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.